[Contraceptive efficiency of triphasic inhibitors (author's transl)]. 1977

W H Schneider, and U Lachnit-Fixson, and R Schmid, and J Spona

The effects of two newly developed triphasic preparations with a sequence of 6/5/10 and a reduced content of the total dose of oestrogen per cycle on the parameters of cycle function were studied in 10 young women with normal phasic cycles using a randomized trial design. Cervical function, spinnbarkeit and crystallisation of cervical secretion and the karyopyknotic index were monitored and LH,E2 and progesterone levels in serum radioimmunologically determined in a pretreatment control cycle, the immediately following 1st treatment cycle, the 3rd treatment cycle and a subsequent treatment-free cycle. Both preparations brought about suppression of ovulation already in the 1st treatment cycle with the periphery (cervical barrier) greatly reduced but still reactive. The results of the study show that by adapting the ratio of active substances to the phases of the normal cycle, not only good cycle control and tolerance are achieved but also inhibition of ovulation.

UI MeSH Term Description Entries
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D008598 Menstruation The periodic shedding of the ENDOMETRIUM and associated menstrual bleeding in the MENSTRUAL CYCLE of humans and primates. Menstruation is due to the decline in circulating PROGESTERONE, and occurs at the late LUTEAL PHASE when LUTEOLYSIS of the CORPUS LUTEUM takes place.
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D009644 Norgestrel A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis. 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)-,DL-Norgestrel,Neogest,Ovrette,Postinor,Wy-3707,DL Norgestrel,Wy 3707,Wy3707
D010060 Ovulation The discharge of an OVUM from a rupturing follicle in the OVARY. Ovulations
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D003276 Contraceptives, Oral Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both. Low-Dose Oral Contraceptive,Oral Contraceptive,Oral Contraceptives,Oral Contraceptives, Low-Dose,Oral Contraceptives, Phasic,Contraceptive, Low-Dose Oral,Contraceptive, Oral,Contraceptives, Low-Dose Oral,Contraceptives, Phasic Oral,Low Dose Oral Contraceptive,Low-Dose Oral Contraceptives,Oral Contraceptive, Low-Dose,Oral Contraceptives, Low Dose,Phasic Oral Contraceptives
D003279 Contraceptives, Oral, Sequential Drugs administered orally and sequentially for contraceptive purposes. Contraceptive Agents, Female Sequential,Contraceptive Agents, Oral, Sequential,Oral Contraceptive Agents, Sequential,Oral Contraceptives, Sequential,Sequential Oral Contraceptive Agents,Contraceptives, Sequential Oral,Sequential Oral Contraceptives
D004997 Ethinyl Estradiol A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-,Ethynyl Estradiol,Estinyl,Ethinyl Estradiol Hemihydrate,Ethinyl Estradiol, (8 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer,Ethinyl Estradiol, (9 beta,17 alpha)-Isomer,Ethinyl-Oestradiol Effik,Ethinylestradiol Jenapharm,Ethinyloestradiol,Lynoral,Microfollin,Microfollin Forte,Progynon C,Estradiol, Ethinyl,Estradiol, Ethynyl,Ethinyl Oestradiol Effik,Hemihydrate, Ethinyl Estradiol,Jenapharm, Ethinylestradiol
D005260 Female Females

Related Publications

W H Schneider, and U Lachnit-Fixson, and R Schmid, and J Spona
September 1973, Ceskoslovenska gynekologie,
W H Schneider, and U Lachnit-Fixson, and R Schmid, and J Spona
October 1985, Drug and therapeutics bulletin,
W H Schneider, and U Lachnit-Fixson, and R Schmid, and J Spona
January 1977, Polski przeglad radiologii i medycyny nuklearnej,
W H Schneider, and U Lachnit-Fixson, and R Schmid, and J Spona
January 1977, Zentralblatt fur Gynakologie,
W H Schneider, and U Lachnit-Fixson, and R Schmid, and J Spona
May 1985, The Medical letter on drugs and therapeutics,
W H Schneider, and U Lachnit-Fixson, and R Schmid, and J Spona
July 1984, The Journal of reproductive medicine,
W H Schneider, and U Lachnit-Fixson, and R Schmid, and J Spona
March 1987, Fertility and sterility,
W H Schneider, and U Lachnit-Fixson, and R Schmid, and J Spona
April 1976, Nihon Funin Gakkai zasshi,
W H Schneider, and U Lachnit-Fixson, and R Schmid, and J Spona
January 1977, Acta neurologica Belgica,
W H Schneider, and U Lachnit-Fixson, and R Schmid, and J Spona
September 1997, Contraception,
Copied contents to your clipboard!